CEPI, SK Biopharma to Develop ‘Variant-Proof’ COVID-19 Vaccine

By PacConAdmin | December 21, 2021

CEPI, the Coalition for Epidemic Preparedness Innovations, has joined with Korean biopharma firm SK bioscience (SK) to develop a “variant-proof” vaccine that would protect against a large coronavirus subgenus that includes the SARS-CoV-2 virus that causes COVID-19.
Source: Drug Industry Daily

Posted in Drug Industry Daily